Clinical trial
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
NCT00001596 · William Gahl, M.D., NIH · Completed
Key facts
| NCT number | NCT00001596 |
|---|---|
| Title | Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome |
| Official title | Therapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome |
| Lead sponsor | William Gahl, M.D., NIH |
| Collaborators | National Human Genome Research Institute (NHGRI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Pulmonary Fibrosis |
| Intervention type | Drug |
| Interventions | Pirfenidone, Placebo |
| Enrollment | 35 |
| Start date | Sep 1, 2005 |
| Primary completion | Sep 1, 2009 |
| Completion | May 9, 2016 |
| First posted | Nov 4, 1999 |
| Last update posted | Oct 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: